Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
| Autor: | Raymond G. McKay, Richard L. Seip, Jeffrey Mather |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Pneumonia Viral Lower risk Severity of Illness Index Gastroenterology Tertiary Care Centers Betacoronavirus 03 medical and health sciences 0302 clinical medicine Internal medicine Intubation Intratracheal medicine Humans Propensity Score Pandemics Aged Retrospective Studies Aged 80 and over Hepatology SARS-CoV-2 business.industry COVID-19 Retrospective cohort study Odds ratio Middle Aged Famotidine medicine.disease Confidence interval COVID-19 Drug Treatment Treatment Outcome 030220 oncology & carcinogenesis Propensity score matching Female 030211 gastroenterology & hepatology Coronavirus Infections business Body mass index Kidney disease medicine.drug |
| Zdroj: | American Journal of Gastroenterology. 115:1617-1623 |
| ISSN: | 1572-0241 0002-9270 |
| DOI: | 10.14309/ajg.0000000000000832 |
| Popis: | Introduction To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine. Methods Retrospective, propensity-matched observational study of consecutive COVID-19-positive patients between February 24, 2020, and May 13, 2020. Results Of 878 patients in the analysis, 83 (9.5%) received famotidine. In comparison to patients not treated with famotidine, patients treated with famotidine were younger (63.5 ± 15.0 vs 67.5 ± 15.8 years, P = 0.021), but did not differ with respect to baseline demographics or preexisting comorbidities. Use of famotidine was associated with a decreased risk of in-hospital mortality (odds ratio 0.37, 95% confidence interval 0.16-0.86, P = 0.021) and combined death or intubation (odds ratio 0.47, 95% confidence interval 0.23-0.96, P = 0.040). Propensity score matching to adjust for age difference between groups did not alter the effect on either outcome. In addition, patients receiving famotidine displayed lower levels of serum markers for severe disease including lower median peak C-reactive protein levels (9.4 vs 12.7 mg/dL, P = 0.002), lower median procalcitonin levels (0.16 vs 0.30 ng/mL, P = 0.004), and a nonsignificant trend to lower median mean ferritin levels (797.5 vs 964.0 ng/mL, P = 0.076). Logistic regression analysis demonstrated that famotidine was an independent predictor of both lower mortality and combined death/intubation, whereas older age, body mass index >30 kg/m, chronic kidney disease, National Early Warning Score, and higher neutrophil-lymphocyte ratio were all predictors of both adverse outcomes. Discussion Famotidine use in hospitalized patients with COVID-19 is associated with a lower risk of mortality, lower risk of combined outcome of mortality and intubation, and lower levels of serum markers for severe disease in hospitalized patients with COVID-19.(Equation is included in full-text article.). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|